This HTML5 document contains 9 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

PrefixNamespace IRI
n11http://dbkwik.webdatacommons.org/ontology/
dctermshttp://purl.org/dc/terms/
n13http://dbkwik.webdatacommons.org/resource/MZ34q721OBFbeIyPrBN4kw==
n7http://dbkwik.webdatacommons.org/resource/4eyOQrusetMh4-IbgG7cMw==
rdfshttp://www.w3.org/2000/01/rdf-schema#
n5http://dbkwik.webdatacommons.org/resource/3iWFJowBqg6jt303VMJRUA==
n12http://dbkwik.webdatacommons.org/resource/OuzUPTeJkSfp75l4nHdYtg==
n4http://dbkwik.webdatacommons.org/diabetes/property/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n2http://dbkwik.webdatacommons.org/resource/7K4g2wLW45pg9jNzn9mrzg==
n3http://dbkwik.webdatacommons.org/resource/k8JH_kpIp9Asr-N9hmCgQg==
xsdhhttp://www.w3.org/2001/XMLSchema#
dbrhttp://dbpedia.org/resource/
Subject Item
n2:
rdfs:label
Insulin aspart
rdfs:comment
Insulin aspart (brand names Novolog[1] and Novorapid[2]) is a rapid-acting insulin produced by Novo Nordisk. It is generally taken at or shortly after mealtimes and has a typical duration profile of three to four hours. Novorapid is approved for insulin pump use as well as to be taken before meals through a syringe.
owl:sameAs
dbr:Insulin_aspart
dcterms:subject
n7:
n3:
300.0
n12:
3600.0
n4:wikiPageUsesTemplate
n5:
n13:
14400.0
n11:abstract
Insulin aspart (brand names Novolog[1] and Novorapid[2]) is a rapid-acting insulin produced by Novo Nordisk. It is generally taken at or shortly after mealtimes and has a typical duration profile of three to four hours. Novorapid is approved for insulin pump use as well as to be taken before meals through a syringe.